J&J’s skin disease drug meets main goals of late-stage study
Johnson & Johnson’s drug for a type of skin condition met the main goals in a late-stage trial, the drugmaker said on Monday.
Related Articles
CVS adds Glenview Capital Management founder to board
CVS has withdrawn its guidance for this year and offered investors no outlook for the next amid struggles in both the pharmacy and insurance businesses.
GenAI Tools and Decision-Making: Beware a New Control Trap | MIT Sloan Management Review
Consider these three takeaways for leaders on how to avoid pitfalls while using generative AI tools in decision-making.
Essential negotiation tips every physician should know [PODCAST]
We dive into the essential skills every physician needs to master in contract negotiation. Internal medicine physician Miguel Villagra offers practical advice on navigating the…
H5N1 bird flu virus in Canadian teenager displays mutations demonstrating virus’ risk
The H5N1 virus that infected a Canadian teen appears not to have spread, but it shows signs of mutation that makes flu virologists nervous.
How Emory’s New Partnership Seeks to Scale Value-Based Care Across Georgia – MedCity News
Emory Healthcare in Atlanta announced a partnership with Guidehealth, value-based care enablement startup. The collaboration is designed to help primary care reach more than 350,000…
Coastal Culture Clash Around AI in Biotech – TimmermanReport.com
“Does the crowd understand? Is it East versus West Or man against man? Can any nation stand alone?” Burning Heart, by Survivor – Rocky IV…
Lilly pill cuts genetic form of cholesterol nearly 86% in study
The highest dose of an experimental pill developed by Eli Lilly dramatically lowered an inherited form of high cholesterol in a mid-stage trial, according to…
Case Study: Pediatric Uvular Cyst
When an 18-month-old patient’s symptoms worsened, pediatric otolaryngologists had to adapt quickly and coordinate care.
EHR vendors step up interoperability efforts
“Discover the latest initiatives in interoperability from Epic, Meditech, and Oracle Health, driving improved data sharing and connectivity in healthcare.”
Pat Koch Thaler, Sister to a Famed Mayor, Chose to Die on a Saturday
Ms. Thaler, a former dean at N.Y.U., used her last interview to reminisce about her brother, Ed, and to publicize the alternatives to prolonging pain…
